Pliant Therapeutics Inc’s recent filing unveils that its President and CEO Coulie Bernard unloaded Company’s shares for reported $0.44 million on Jan 17 ’24. In the deal valued at $17.23 per share,25,721 shares were sold. As a result of this transaction, Coulie Bernard now holds 316,382 shares worth roughly $4.2 million.
Then, Lefebvre Eric sold 10,295 shares, generating $177,383 in total proceeds. Upon selling the shares at $17.23, the Chief Medical Officer now owns 156,920 shares.
Before that, Hull Hans sold 9,786 shares. Pliant Therapeutics Inc shares valued at $168,613 were divested by the Chief Business Officer at a price of $17.23 per share. As a result of the transaction, Hull Hans now holds 185,069 shares, worth roughly $2.45 million.
Wells Fargo initiated its Pliant Therapeutics Inc [PLRX] rating to an Overweight in a research note published on December 08, 2023; the price target was $41. A number of analysts have revised their coverage, including Canaccord Genuity’s analysts, who began to cover the stock in mid May with a ‘”a Buy”‘ rating. Robert W. Baird began covering PLRX with “an Outperform” recommendation on April 13, 2023. Stifel started covering the stock on December 14, 2022. It rated PLRX as “a Buy”.
Price Performance Review of PLRX
On Tuesday, Pliant Therapeutics Inc [NASDAQ:PLRX] saw its stock fall -2.14% to $13.26. Over the last five days, the stock has lost -11.13%. Pliant Therapeutics Inc shares have fallen nearly -26.78% since the year began. Nevertheless, the stocks have fallen -49.96% over the past one year. While a 52-week high of $30.85 was reached on 01/08/24, a 52-week low of $12.60 was recorded on 04/16/24. SMA at 50 days reached $15.39, while 200 days put it at $16.23. A total of 0.43 million shares were traded, compared to the trading of 0.21 million shares in the previous session.
Levels Of Support And Resistance For PLRX Stock
The 24-hour chart illustrates a support level at 13.10, which if violated will result in even more drops to 12.94. On the upside, there is a resistance level at 13.54. A further resistance level may holdings at 13.82. The Relative Strength Index (RSI) on the 14-day chart is 33.87, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.76, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 97.98%. Stochastics %K at 7.99% indicates the stock is a buying.
The most recent change occurred on December 07, 2022 when JP Morgan began covering the stock and recommended ‘”an Overweight”‘ rating along with a $42 price target.
